<DOC>
	<DOCNO>NCT00888108</DOCNO>
	<brief_summary>This Phase 1 open-label study evaluate safety ABT-263 combined standard weekly regimen docetaxel subject solid tumor measurable disease .</brief_summary>
	<brief_title>Safety Profile , MTD , PK Profile Studies ABT-263 When Administered Combination With Standard Weekly Regimens Docetaxel Subjects With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<criteria>Inclusion Criteria Subject must great equal 18 year age . Subject must histologically and/or cytologically documented cancer docetaxel determine appropriate therapy , per Investigator . Subject must evaluable and/or measurable disease Computed Tomography ( CT ) Magnetic Resonance Imaging ( MRI ) define RECIST . Subjects brain metastasis must clinically control neurologic symptom , define surgical excision and/or radiation therapy follow 21 day stable neurologic function evidence CNS disease progression determine CT MRI within 28 day prior first dose study drug . Subject Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 1 . Subject must adequate bone marrow , renal hepatic function per local laboratory reference range follow : Bone marrow : Absolute Neutrophil Count ( ANC ) great equal 1500/microliters ; platelet great equal 150,000/mm^3 ; hemoglobin great equal 9.0 g/dL ; Renal function : Serum creatinine less equal 2.0 mg/dL calculate creatinine clearance great equal 50 mL/min ; Hepatic function enzyme : AST ALT less equal 1.5 x upper limit normal ( ULN ) institution 's normal range , ALP le equal 2.5 x ULN , bilirubin le equal 1.0 x ULN . Subjects bone metastasis may ALP less equal 5.0 x ULN . Coagulation : aPTT PT exceed less equal 1.2 x ULN . Female subject must surgically sterile , postmenopausal ( least one year ) , negative result pregnancy test perform follow : At Screening via serum sample obtain within 14 day prior initial study drug administration , Prior dose via urine sample obtain Cycle 1 Day 1 , great 7 day since obtain serum pregnancy test result . Female subject surgically sterile postmenopausal ( least one year ) nonvasectomized male subject must practice least one follow method birth control : total abstinence sexual intercourse ( minimum one complete menstrual cycle ) ; vasectomize partner ; hormonal contraceptive ( oral , parenteral transdermal ) least three month prior study drug administration ; Doublebarrier method ( include condom , contraceptive sponge , diaphragm vaginal ring spermicidal jelly cream ) . The subject , legal representative , must voluntarily sign date inform consent , approve Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) , prior initiation screen studyspecific procedure . Exclusion Criteria The subject underlying , predispose condition bleed currently exhibit sign bleed . The subject recent history thrombocytopenia associate bleed within 1 year prior first dose study drug . The subject currently receive require anticoagulation therapy drug herbal supplement affect platelet function , exception lowdose anticoagulation medication ( i.e. , Heparin ) use maintain patency central intravenous catheter . A female subject pregnant breastfeeding . The subject active peptic ulcer disease potentially hemorrhagic esophagitis/gastritis . The subject active immune thrombocytopenic purpura ( ITP ) , autoimmune hemolytic anemia ( AIHA ) , history refractory platelet transfusion ( within 1 year prior first dose study drug ) . The subject receive anticancer therapy include chemotherapy , immunotherapy , radiotherapy , hormonal therapy ( exception hormone hypothyroidism , estrogen replacement therapy [ ERT ] , anti estrogen analog , agonist require suppress serum testosterone level [ e.g. , LHRH , GnRH , etc . ] subject prostate cancer stable dose least 21 day prior first dose study drug ) , investigational therapy 14 day prior first dose study drug , recover less grade 2 clinically significant adverse effect ( ) /toxicity ( ) previous therapy . The subject receive antibody therapy biologic ( exception colony stimulate factor [ GCSF , GMCSF ] erythropoietin ) within 28 day prior first dose study drug . The subject consume grapefruit grapefruit product within 3 day prior first dose study drug . The subject receive steroid therapy antineoplastic intent within 7 day prior first dose study drug exception inhale steroid asthma , topical steroid , replacement/stress corticosteroid , corticosteroid take premedication study . The subject receive aspirin know CYP3A inhibitor ( e.g. , ketoconazole ) within 7 day prior first dose study drug . The subject undergone allogeneic stem cell transplant . The subject receive radioimmunotherapy within 6 month prior first dose study drug . The subject history hypersensitivity docetaxel polysorbate 80 drug . The subject test positive human immunodeficiency virus , HIV ( due potential drugdrug interaction antiretroviral medication navitoclax ( ABT263 ) , well anticipate navitoclax ( ABT263 ) mechanism base lymphopenia may potentially increase risk opportunistic infection potential drugdrug interaction certain anti infective agent ) . The subject significant history cardiovascular ( e.g. , MI , thrombotic thromboembolic event last 6 month ) , renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , hepatic disease opinion investigator would adversely affect his/her participate study . Questions regard inclusion individual subject direct Abbott Medical Monitor designee . The subject exhibit evidence clinically significant uncontrolled condition ( ) include , limited : active systemic fungal infection ; A diagnosis fever neutropenia within 1 week prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>